Aeglea BioTherapeutics
Drugs for the treatment of tumors the company was incorporated in 2013 and is based in texas.
Launch date
Employees
Market cap
€1.4b
Enterprise valuation
€1.0b (Public information from Sep 2024)
Share price
$30.4 AGLE
Austin Texas (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | 18.7m | 2.3m | <1m | 3.3m | 5.0m | <1m |
% growth | - | - | (88 %) | (62 %) | 276 % | 50 % | (95 %) |
EBITDA | (80.5m) | (65.6m) | (84.8m) | (242m) | (170m) | (178m) | - |
% EBITDA margin | - | (350 %) | (3640 %) | (27269 %) | (5098 %) | (3560 %) | - |
Profit | (80.9m) | (65.8m) | (83.8m) | (339m) | (169m) | (194m) | (235m) |
% profit margin | - | (351 %) | (3599 %) | (38239 %) | (5065 %) | (3884 %) | (93920 %) |
EV / revenue | - | 12.5x | 11.9x | 491.6x | 330.9x | 179.8x | 5840.0x |
EV / EBITDA | -4.7x | -3.6x | -0.3x | -1.8x | -6.5x | -5.0x | - |
R&D budget | 59.6m | 57.1m | 58.6m | - | - | - | - |
R&D % of revenue | - | 305 % | 2515 % | - | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$12.0m | Series A | ||
$44.0m | Series B | ||
N/A | N/A | IPO | |
* | $210m | Post IPO Convertible | |
Total Funding | €50.9m |
Recent News about Aeglea BioTherapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Aeglea BioTherapeutics
EditACQUISITION by Aeglea BioTherapeutics Jun 2023